Skip to main content
Top
Published in: Inflammation Research 9/2012

01-09-2012 | Original Research Paper

Long-term treatment with methanandamide attenuates LPS-induced periodontitis in rats

Authors: Cesar A. Ossola, Pablo N. Surkin, Antonela Pugnaloni, Claudia E. Mohn, Juan C. Elverdin, Javier Fernandez-Solari

Published in: Inflammation Research | Issue 9/2012

Login to get access

Abstract

Objective

Evidence exists of the anti-inflammatory and immunological properties of endocannabinoids in various tissues; the aim of the present study was therefore to assess the effect of long-term treatment with the synthetic cannabinoid methanandamide (Meth-AEA) on the progression of periodontitis in rats.

Materials and methods

Periodontitis was induced by injecting LPS (1 mg/ml) into the gingiva around the neck of the first upper and lower molars, and into the inter-dental space between the first and second molars. This protocol was repeated for 6 weeks on days 1, 3, and 5 of each week.

Results

Long-term treatment with topical Meth-AEA (500 ng/ml), applied daily to gingival tissue of rats induced with periodontitis, significantly diminished the alveolar bone loss, measured as the distance between the cemento-enamel junction and the alveolar crest, in both maxillary and mandibular first molars, compared to rats without treatment (P < 0.05). The treatment also reduced the production of some biological mediators of periodontal disease augmented by LPS, such as tumor necrosis factor alpha (from 119.4 ± 9.9 pg/mg protein to 75.1 ± 10.8, P < 0.05) and nitric oxide produced by inducible nitric oxide synthase (from 507.7 ± 107.1 pmol/min/mg protein to 163.1 ± 53.9, P < 0.01).

Conclusion

These results demonstrate the beneficial effects of treatment with Meth-AEA on gingival tissue of rats with periodontitis.
Literature
1.
go back to reference Taubman MA, Valverde P, Han X, Kawai T. Immune response: the key to bone resorption in periodontal disease. J Periodontol. 2005;76:2033–41.PubMedCrossRef Taubman MA, Valverde P, Han X, Kawai T. Immune response: the key to bone resorption in periodontal disease. J Periodontol. 2005;76:2033–41.PubMedCrossRef
2.
go back to reference Prestifilippo JP, Carabajal E, Croci M, Fernández-Solari J, Rivera ES, Elverdin JC, Medina VA. Histamine modulates salivary secretion and diminishes the progression of periodontal disease in rat experimental periodontitis. Inflamm Res. 2012;61:455–61. doi:10.1007/s00011-011-0432-4.PubMedCrossRef Prestifilippo JP, Carabajal E, Croci M, Fernández-Solari J, Rivera ES, Elverdin JC, Medina VA. Histamine modulates salivary secretion and diminishes the progression of periodontal disease in rat experimental periodontitis. Inflamm Res. 2012;61:455–61. doi:10.​1007/​s00011-011-0432-4.PubMedCrossRef
3.
go back to reference Slomiany BL, Slomiany A. Porphyromonas gingivalis lipopolysaccharide-induced cytosolic phospholipase A2 activation interferes with salivary mucin synthesis via platelet activating factor generation. Inflammopharmacology. 2006;14:144–9.PubMedCrossRef Slomiany BL, Slomiany A. Porphyromonas gingivalis lipopolysaccharide-induced cytosolic phospholipase A2 activation interferes with salivary mucin synthesis via platelet activating factor generation. Inflammopharmacology. 2006;14:144–9.PubMedCrossRef
4.
go back to reference Palsson-McDermott EM, O’Neill LA. Signal transduction by the lipopolysaccharide receptor, toll-like receptor-4. Immunology. 2004;113:153–62.PubMedCrossRef Palsson-McDermott EM, O’Neill LA. Signal transduction by the lipopolysaccharide receptor, toll-like receptor-4. Immunology. 2004;113:153–62.PubMedCrossRef
5.
go back to reference Amer M, Elverdin JC, Fernández-Solari J, Medina VA, Chiarenza AP, Vacas MI. Reduced methacholine-induced submandibular salivary secretion in rats with experimental periodontitis. Arch Oral Biol. 2011;56:421–7.PubMedCrossRef Amer M, Elverdin JC, Fernández-Solari J, Medina VA, Chiarenza AP, Vacas MI. Reduced methacholine-induced submandibular salivary secretion in rats with experimental periodontitis. Arch Oral Biol. 2011;56:421–7.PubMedCrossRef
6.
go back to reference Tatakis DN. Interleukin-1 and bone metabolism: a review. J Periodontol. 1993;64:416–31.PubMed Tatakis DN. Interleukin-1 and bone metabolism: a review. J Periodontol. 1993;64:416–31.PubMed
7.
go back to reference Rink L, Kirchner H. Recent progress in the tumor necrosis factor-alpha field. Int Arch Allergy Immunol. 1996;111:199–209.PubMedCrossRef Rink L, Kirchner H. Recent progress in the tumor necrosis factor-alpha field. Int Arch Allergy Immunol. 1996;111:199–209.PubMedCrossRef
8.
9.
go back to reference Offenbacher S, Heasman PA, Collins JG. Modulation of host PGE2 secretion as a determinant of periodontal disease expression. J Periodontol. 1993;64:432–44.PubMed Offenbacher S, Heasman PA, Collins JG. Modulation of host PGE2 secretion as a determinant of periodontal disease expression. J Periodontol. 1993;64:432–44.PubMed
10.
go back to reference Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem. 1994;37:1889–93.PubMedCrossRef Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem. 1994;37:1889–93.PubMedCrossRef
11.
go back to reference Yates ML, Barker EL. Inactivation and biotransformation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol. Mol Pharmacol. 2009;76:11–7.PubMedCrossRef Yates ML, Barker EL. Inactivation and biotransformation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol. Mol Pharmacol. 2009;76:11–7.PubMedCrossRef
12.
go back to reference Kupczyk P, Reich A, Szepietowski JC. Cannabinoid system in the skin—a possible target for future therapies in dermatology. Exp Dermatol. 2009;18:669–79.PubMedCrossRef Kupczyk P, Reich A, Szepietowski JC. Cannabinoid system in the skin—a possible target for future therapies in dermatology. Exp Dermatol. 2009;18:669–79.PubMedCrossRef
13.
go back to reference Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1:1333–49.PubMedCrossRef Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1:1333–49.PubMedCrossRef
14.
go back to reference Mallat A, Lotersztajn S. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. Am J Physiol Gastrointest Liver Physiol. 2008;294:G9–12.PubMedCrossRef Mallat A, Lotersztajn S. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. Am J Physiol Gastrointest Liver Physiol. 2008;294:G9–12.PubMedCrossRef
15.
go back to reference Garcia-Ovejero D, Arevalo-Martin A, Petrosino S, et al. The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis. 2009;33:57–71.PubMedCrossRef Garcia-Ovejero D, Arevalo-Martin A, Petrosino S, et al. The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis. 2009;33:57–71.PubMedCrossRef
16.
go back to reference Izzo AA, Camilleri M. Cannabinoids in intestinal inflammation and cancer. Pharmacol Res. 2009;60:117–25.PubMedCrossRef Izzo AA, Camilleri M. Cannabinoids in intestinal inflammation and cancer. Pharmacol Res. 2009;60:117–25.PubMedCrossRef
17.
go back to reference Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A. Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol. 2008;20:69–74.PubMedCrossRef Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A. Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol. 2008;20:69–74.PubMedCrossRef
18.
go back to reference Kozono S, Matsuyama T, Biwasa KK, et al. Involvement of the endocannabinoid system in periodontal healing. Biochem Biophys Res Commun. 2010;394:928–33.PubMedCrossRef Kozono S, Matsuyama T, Biwasa KK, et al. Involvement of the endocannabinoid system in periodontal healing. Biochem Biophys Res Commun. 2010;394:928–33.PubMedCrossRef
19.
go back to reference Llavaneras A, Ramamurthy NS, Heikkilä P, et al. A combination of a chemically modified doxycycline and a bisphosphonate synergistically inhibits endotoxininduced periodontal breakdown in rats. J Periodontol. 2001;72:1069–77.PubMedCrossRef Llavaneras A, Ramamurthy NS, Heikkilä P, et al. A combination of a chemically modified doxycycline and a bisphosphonate synergistically inhibits endotoxininduced periodontal breakdown in rats. J Periodontol. 2001;72:1069–77.PubMedCrossRef
20.
go back to reference Gürkan A, Emingil G, Nizam N, Doğanavşargil B, Sezak M, Kütükçüler N, Atilla G. Therapeutic efficacy of vasoactive intestinal peptide in escherichia coli lipopolysaccharide-induced experimental periodontitis in rats. J Periodontol. 2009;80:1655–64.PubMedCrossRef Gürkan A, Emingil G, Nizam N, Doğanavşargil B, Sezak M, Kütükçüler N, Atilla G. Therapeutic efficacy of vasoactive intestinal peptide in escherichia coli lipopolysaccharide-induced experimental periodontitis in rats. J Periodontol. 2009;80:1655–64.PubMedCrossRef
21.
go back to reference Prestifilippo JP, Fernández-Solari J, Medina V, Rettori V, Elverdin JC. Role of the endocannabinoid system in ethanol-induced inhibition of salivary secretion. Alcohol Alcohol. 2009;44:443–8.PubMed Prestifilippo JP, Fernández-Solari J, Medina V, Rettori V, Elverdin JC. Role of the endocannabinoid system in ethanol-induced inhibition of salivary secretion. Alcohol Alcohol. 2009;44:443–8.PubMed
22.
go back to reference Prestifilippo JP, Fernández-Solari J, de la Cal C, Iribarne M, Suburo AM, Rettori V, McCann SM, Elverdin JC. Inhibition of salivary secretion by activation of endocannabinoid receptors. Exp Biol Med. 2006;231:1421–9. Prestifilippo JP, Fernández-Solari J, de la Cal C, Iribarne M, Suburo AM, Rettori V, McCann SM, Elverdin JC. Inhibition of salivary secretion by activation of endocannabinoid receptors. Exp Biol Med. 2006;231:1421–9.
23.
go back to reference Lin S, Khanolkar AD, Fan P, Goutopoulos A, Qin C, Papahadjis D, Makriyannis A. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem. 1998;41:5353–61.PubMedCrossRef Lin S, Khanolkar AD, Fan P, Goutopoulos A, Qin C, Papahadjis D, Makriyannis A. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem. 1998;41:5353–61.PubMedCrossRef
24.
go back to reference Goutopoulos A, Fan P, Khanolkar AD, Xie XQ, Lin S, Makriyannis A. Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability. Bioorg Med Chem. 2001;9:1673–84.PubMedCrossRef Goutopoulos A, Fan P, Khanolkar AD, Xie XQ, Lin S, Makriyannis A. Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability. Bioorg Med Chem. 2001;9:1673–84.PubMedCrossRef
25.
go back to reference Crawford JM, Taubman MA, Smith DJ. The natural history of periodontal bone loss in germfree and gnotobiotic rats infected with periodontopathic microorganisms. J Periodontal Res. 1978;13:316–25.PubMedCrossRef Crawford JM, Taubman MA, Smith DJ. The natural history of periodontal bone loss in germfree and gnotobiotic rats infected with periodontopathic microorganisms. J Periodontal Res. 1978;13:316–25.PubMedCrossRef
26.
go back to reference Vacas MI, Amer M, Chiarenza AP, Luchelli MA, Mandalunis PM, Elverdin JC. Influence of submandibulectomy on alveolar bone loss in rats. J Periodontol. 2008;79:1075–80.PubMedCrossRef Vacas MI, Amer M, Chiarenza AP, Luchelli MA, Mandalunis PM, Elverdin JC. Influence of submandibulectomy on alveolar bone loss in rats. J Periodontol. 2008;79:1075–80.PubMedCrossRef
27.
go back to reference Bredt DS, Snyder SH. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci USA. 1989;86:9030–3.PubMedCrossRef Bredt DS, Snyder SH. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci USA. 1989;86:9030–3.PubMedCrossRef
28.
go back to reference Mohn CE, Fernandez-Solari J, De Laurentiis A, Bornstein SR, Ehrhart-Bornstein M, Rettori V. Adrenal gland responses to lipopolysaccharide after stress and ethanol administration in male rats. Stress. 2011;14:216–26.PubMed Mohn CE, Fernandez-Solari J, De Laurentiis A, Bornstein SR, Ehrhart-Bornstein M, Rettori V. Adrenal gland responses to lipopolysaccharide after stress and ethanol administration in male rats. Stress. 2011;14:216–26.PubMed
29.
go back to reference Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, Barrett DA, Kendall DA, Scammell BE, Reeve AJ, Chapman V. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther. 2008;10:R43.PubMedCrossRef Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, Barrett DA, Kendall DA, Scammell BE, Reeve AJ, Chapman V. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther. 2008;10:R43.PubMedCrossRef
30.
go back to reference Idris AI, Sophocleous A, Landao-Bassonga E, van’t Hof RJ, Ralston SH. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology. 2008;149:5619–26.PubMedCrossRef Idris AI, Sophocleous A, Landao-Bassonga E, van’t Hof RJ, Ralston SH. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology. 2008;149:5619–26.PubMedCrossRef
31.
go back to reference Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J. Cannabinoids: novel medicines for the treatment of Huntington’s disease. Recent Pat CNS Drug Discov. 2012;7:41–8.PubMedCrossRef Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J. Cannabinoids: novel medicines for the treatment of Huntington’s disease. Recent Pat CNS Drug Discov. 2012;7:41–8.PubMedCrossRef
32.
go back to reference Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72:735–44.PubMedCrossRef Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72:735–44.PubMedCrossRef
33.
go back to reference Nakajima Y, Furuichi Y, Biswas KK, Hashiguchi T, Kawahara K, Yamaji K, Uchimura T, Izumi Y, Maruyama I. Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF-kappaB pathway inhibition. FEBS Lett. 2006;580:613–9.PubMedCrossRef Nakajima Y, Furuichi Y, Biswas KK, Hashiguchi T, Kawahara K, Yamaji K, Uchimura T, Izumi Y, Maruyama I. Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF-kappaB pathway inhibition. FEBS Lett. 2006;580:613–9.PubMedCrossRef
34.
go back to reference Preshaw PM, Heasman PA. Prostaglandin E2 concentrations in gingival crevicular fluid: observation in untreated chronic periodontitis. J Clin Periodontol. 2002;29:15–20.PubMedCrossRef Preshaw PM, Heasman PA. Prostaglandin E2 concentrations in gingival crevicular fluid: observation in untreated chronic periodontitis. J Clin Periodontol. 2002;29:15–20.PubMedCrossRef
35.
go back to reference Ekuni D, Endo Y, Irie K, Azuma T, Tamaki N, Tomofuji T, et al. Imbalance of oxidative/anti-oxidative status induced by periodontitis is involved in apoptosis of rat submandibular glands. Arch Oral Biol. 2010;55:170–6.PubMedCrossRef Ekuni D, Endo Y, Irie K, Azuma T, Tamaki N, Tomofuji T, et al. Imbalance of oxidative/anti-oxidative status induced by periodontitis is involved in apoptosis of rat submandibular glands. Arch Oral Biol. 2010;55:170–6.PubMedCrossRef
36.
go back to reference Scannapieco FA, Dasanayake AP, Chhun N. Does periodontal therapy reduce the risk for systemic diseases? Dent Clin N Am. 2010;54:163–81.PubMedCrossRef Scannapieco FA, Dasanayake AP, Chhun N. Does periodontal therapy reduce the risk for systemic diseases? Dent Clin N Am. 2010;54:163–81.PubMedCrossRef
37.
go back to reference Fowler EB, Breault LG, Cuenin MF. Periodontal disease and its association with systemic disease. Mil Med. 2001;166:85–9.PubMed Fowler EB, Breault LG, Cuenin MF. Periodontal disease and its association with systemic disease. Mil Med. 2001;166:85–9.PubMed
38.
go back to reference Lappin DF, Kjeldsen M, Sander L, Kinane DF. Inducible nitric oxide synthase expression in periodontitis. J Periodontal Res. 2000;5:369–73.CrossRef Lappin DF, Kjeldsen M, Sander L, Kinane DF. Inducible nitric oxide synthase expression in periodontitis. J Periodontal Res. 2000;5:369–73.CrossRef
39.
go back to reference Brandi ML, Hukkanen M, Umeda T, Moradi-Bidhendi N, Bianchi S, Gross SS, Polak JM, MacIntyre I. Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proc Natl Acad Sci USA. 1995;92:2954–8.PubMedCrossRef Brandi ML, Hukkanen M, Umeda T, Moradi-Bidhendi N, Bianchi S, Gross SS, Polak JM, MacIntyre I. Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proc Natl Acad Sci USA. 1995;92:2954–8.PubMedCrossRef
40.
go back to reference Ralston SH, Ho LP, Helfrich MH, Grabowski PS, Johnston PW, Benjamin N. Nitric oxide: a cytokine-induced regulator of bone resorption. J Bone Miner Res. 1995;10:1040–9.PubMedCrossRef Ralston SH, Ho LP, Helfrich MH, Grabowski PS, Johnston PW, Benjamin N. Nitric oxide: a cytokine-induced regulator of bone resorption. J Bone Miner Res. 1995;10:1040–9.PubMedCrossRef
41.
go back to reference Karmaus PW, Chen W, Crawford RB, Harkema JR, Kaplan BL, Kaminski NE. Deletion of cannabinoid receptors 1 and 2 exacerbates APC function to increase inflammation and cellular immunity during influenza infection. J Leukoc Biol. 2011;90:983–95.PubMedCrossRef Karmaus PW, Chen W, Crawford RB, Harkema JR, Kaplan BL, Kaminski NE. Deletion of cannabinoid receptors 1 and 2 exacerbates APC function to increase inflammation and cellular immunity during influenza infection. J Leukoc Biol. 2011;90:983–95.PubMedCrossRef
42.
go back to reference Darling MR, Arendorf TM. Review of the effects of cannabis smoking on oral health. Int Dent J. 1992;42:19–22.PubMed Darling MR, Arendorf TM. Review of the effects of cannabis smoking on oral health. Int Dent J. 1992;42:19–22.PubMed
43.
go back to reference Nogueira-Filho GR, Todescan S, Shah A, Rosa BT, Tunes Uda R, Cesar Neto JB. Impact of cannabis sativa (marijuana) smoke on alveolar bone loss: a histometric study in rats. J Periodontol. 2011;82:1602–7.PubMedCrossRef Nogueira-Filho GR, Todescan S, Shah A, Rosa BT, Tunes Uda R, Cesar Neto JB. Impact of cannabis sativa (marijuana) smoke on alveolar bone loss: a histometric study in rats. J Periodontol. 2011;82:1602–7.PubMedCrossRef
44.
go back to reference Pertwee RG. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forsch Komplementarmed. 1999;6:12–5.PubMedCrossRef Pertwee RG. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forsch Komplementarmed. 1999;6:12–5.PubMedCrossRef
45.
go back to reference Walker JM, Strangman NM, Huang SM. Cannabinoids and pain. Pain Res Manag. 2001;6:74–9.PubMed Walker JM, Strangman NM, Huang SM. Cannabinoids and pain. Pain Res Manag. 2001;6:74–9.PubMed
46.
go back to reference Di Marzo V, Piscitelli F, Mechoulam R. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol. 2011;203:75–104.PubMedCrossRef Di Marzo V, Piscitelli F, Mechoulam R. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol. 2011;203:75–104.PubMedCrossRef
47.
go back to reference Kurzthaler I, Hummer M, Miller C, Sperner-Unterweger B, Günther V, Wechdorn H, Battista HJ, Fleischhacker WW. Effect of cannabis use on cognitive functions and driving ability. J Clin Psychiatry. 1999;60:395–9.PubMedCrossRef Kurzthaler I, Hummer M, Miller C, Sperner-Unterweger B, Günther V, Wechdorn H, Battista HJ, Fleischhacker WW. Effect of cannabis use on cognitive functions and driving ability. J Clin Psychiatry. 1999;60:395–9.PubMedCrossRef
48.
go back to reference Lutz B. On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem Pharmacol. 2004;68:1691–8.PubMedCrossRef Lutz B. On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem Pharmacol. 2004;68:1691–8.PubMedCrossRef
Metadata
Title
Long-term treatment with methanandamide attenuates LPS-induced periodontitis in rats
Authors
Cesar A. Ossola
Pablo N. Surkin
Antonela Pugnaloni
Claudia E. Mohn
Juan C. Elverdin
Javier Fernandez-Solari
Publication date
01-09-2012
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 9/2012
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-012-0485-z

Other articles of this Issue 9/2012

Inflammation Research 9/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.